T0	Outcomes 0 19	Efficacy and safety
T1	Outcomes 528 547	efficacy and safety
T2	Outcomes 1251 1349	change in neuropathy between baseline and week 48, demonstrated by the Neuropathy Impairment Score
T3	Outcomes 1438 1692	quantitative sensory tests using the CASE IV System, the Neuropathy Symptom and Change questionnaire, the Patient Benefit Questionnaire (PBQ), and a global symptom assessment, as well as nerve conduction studies and occurrence of new plantar foot ulcers.
T4	Outcomes 1738 1753	adverse events.
T5	Outcomes 1918 1932	adverse events
T6	Outcomes 1978 2026	site pain/hyperalgesia and other pain syndromes.
T7	Outcomes 2177 2202	global symptom assessment